Tarceva shows survival benefit in maintenance setting in lung cancer
This article was originally published in Scrip
Executive Summary
Roche (Genentech)/OSI Pharmaceuticals' EGFR inhibitor Tarceva (erlotinib) has prolonged overall survival by one month to 12 months when used as a maintenance therapy in advanced non-small cell lung cancer (NSCLC) compared with placebo in the pivotal Phase III SATURN trial.